• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    10/31/24 1:36:40 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EGRX alert in real time by email
    SC 13G/A 1 unionsquare-egrx103024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    EAGLE PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

    (Title of Class of Securities)

     

    269796108

    (CUSIP Number)

     

     

    October 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  269796108
     SCHEDULE 13G/A
    Page 2 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Union Square Park Partners, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,321,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,321,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,321,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.17%
    12
    TYPE OF REPORTING PERSON
     
    PN

     


     

    CUSIP No.  269796108
     SCHEDULE 13G/A
    Page 3 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Union Square Park Capital Management, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,321,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,321,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,321,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.17%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

    CUSIP No.  269796108
     SCHEDULE 13G/A
    Page 4 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Union Square Park GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,321,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,321,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,321,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.17%
    12
    TYPE OF REPORTING PERSON
     
    OO
     


     

    CUSIP No.  269796108
     SCHEDULE 13G/A
    Page 5 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Leon Zaltzman
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,321,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,321,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,321,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.17%
    12
    TYPE OF REPORTING PERSON
     
    IN
     


     

     

    CUSIP No. 269796108
     SCHEDULE 13G/A
    Page 6 of 10 Pages

     

    Item 1.(a) Name of Issuer

    EAGLE PHARMACEUTICALS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    50 Tice Boulevard, Suite 315

    Woodcliff Lake, NJ 07677

    Item 2.(a) Names of Persons Filing:

    Union Square Park Partners, LP

    Union Square Park Capital Management, LLC

    Union Square Park GP, LLC

    Leon Zaltzman

    (b) Address of Principal Business Office:

    Union Square Park Partners, LP, 1120 Avenue of the Americas, Suite 1502, New York, NY, 10036

    Union Square Park Capital Management, LLC,1120 Avenue of the Americas, Suite 1502, New York, NY, 10036

    Union Square Park GP, LLC, 1120 Avenue of the Americas, Suite 1502, New York, NY, 10036

    Leon Zaltzman, 1120 Avenue of the Americas, Suite 1502, New York, NY, 10036

    (c) Citizenship:

    Please refer to Item 4 on each cover sheet for each filing person.

      

    Item 2.(d) Title of Class of Securities

    Common stock, par value $0.0001 per share

     

    Item 2.(e) CUSIP No.:

    269796108

     

    CUSIP No.  269796108
     SCHEDULE 13G/A
    Page 7 of 10 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

    Not applicable

     

     

    CUSIP No. 269796108
     SCHEDULE 13G/A
    Page 8 of 10 Pages

     

     

    Item 4. Ownership

    (a) Amount beneficially owned: 1,321,385

    (b) Percent of class: 10.17%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 1,321,385

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 1,321,385

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 269796108
     SCHEDULE 13G/A
    Page 9 of 10 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 31, 2024

     

     

     

     

    Union Square Park Partners, LP

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member of the General Partner

           
     

    Union Square Park Capital Management, LLC

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member

           
     

    Union Square Park GP, LLC

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member

           
     

    Leon Zaltzman

           
       /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

           

     

     
    CUSIP No. 269796108
     SCHEDULE 13G/A
    Page 10 of 10 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: October 31, 2024

     

     

    Union Square Park Partners, LP

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member of the General Partner

           
     

    Union Square Park Capital Management, LLC

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member

           
     

    Union Square Park GP, LLC

           
      By:  /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Title: Managing Member

           
     

    Leon Zaltzman

           
       /s/ Leon Zaltzman
       

    Name: Leon Zaltzman

    Get the next $EGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EGRX

    DatePrice TargetRatingAnalyst
    8/10/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    8/9/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    More analyst ratings

    $EGRX
    Financials

    Live finance-specific insights

    See more
    • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

      3/21/25 4:30:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

      10/31/24 8:00:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Delays Third Quarter 2023 Results and Conference Call

      WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

      11/9/23 7:30:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eagle Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

      8/10/23 7:32:29 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

      8/9/23 10:15:46 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts resumed coverage on Eagle Pharma with a new price target

      RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00

      4/7/21 6:39:38 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      11/14/24 11:34:47 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      11/5/24 4:32:23 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      10/31/24 1:36:40 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eagle Pharmaceuticals Inc.

      15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      1/24/25 4:08:37 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Eagle Pharmaceuticals Inc.

      EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      12/10/24 12:15:03 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      12/2/24 4:17:10 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Leadership Updates

    Live Leadership Updates

    See more

    $EGRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

      WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

      11/12/24 7:00:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

      WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d

      7/18/22 6:50:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

      Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her

      5/3/21 6:50:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

      WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. ("Blue Owl") (the "Agreement"), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.   BENDEKA is a ready-to-dilute liquid, low-volume (50 mL) and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphoc

      3/31/25 4:00:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

      3/21/25 4:30:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

      WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that it has notified The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the "SEC") to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC. As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to

      11/15/24 5:00:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Krawtschuk Christopher

      3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      11/19/24 7:59:53 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tarriff Scott covered exercise/tax liability with 2,119 shares, decreasing direct ownership by 0.46% to 460,621 units (SEC Form 4)

      4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      3/1/24 4:40:02 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cahill Brian Joseph was granted 3,800 shares and covered exercise/tax liability with 1,589 shares, increasing direct ownership by 5% to 47,958 units (SEC Form 4)

      4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      2/29/24 8:23:05 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care